10-Q: Entera Bio Reports Q3 2025 Losses Amid Clinical Progress

Entera Bio Ltd. reported increased operating losses for Q3 and the nine months ended September 30, 2025, despite advancing its oral peptide pipeline and securing new funding through a collaboration with OPKO.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $8.423 million from $7.183 million in the prior year period.
• Operating loss for the nine months ended September 30, 2025, rose to $8.487 million, up 17% from $7.248 million in the same period of 2024.
• Research and development expenses increased by 30% to $4.286 million for the nine months ended September 30, 2025, primarily due to EB613 program preparation and OPKO collaboration.
• Cash and cash equivalents stood at $8.574 million as of September 30, 2025, with an additional $8.028 million in restricted cash designated for the OPKO collaboration.
• The company's accumulated deficit reached $122.350 million as of September 30, 2025.
• FDA agreed that a single multinational Phase 3 study for EB613 (oral PTH(1-34) for osteoporosis) with Total Hip BMD as the primary endpoint and vertebral fractures as a key secondary endpoint would support an NDA filing.
• A new generation of EB613 initiated a Phase 1 Safety and PK Study in November 2025.
• The collaboration with OPKO for oral oxyntomodulin (OXM) for obesity and metabolic disorders is progressing, with an IND application expected in the first half of 2026.
• The company raised $8.0 million from OPKO through an equity issuance as part of the 2025 Collaboration Agreement, with proceeds escrowed for development costs.
• Existing cash resources are projected to be sufficient to fund operations through the middle of the third quarter of 2026, excluding the capital required for the EB613 Phase 3 program.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is significant positive clinical and collaboration progress, the substantial increase in net and operating losses, coupled with the explicit 'going concern' warning and the need for significant additional capital for the lead program, weighs heavily on the financial outlook. The geopolitical risks, though currently immaterial, add an element of uncertainty.

Positives

• FDA concurrence on a single Phase 3 study design for EB613 significantly streamlines the regulatory pathway for its osteoporosis treatment.
• Positive preclinical data for Next-Gen EB613 shows comparable pharmacokinetics to the current formulation, indicating potential for improved efficacy or patient experience.
• Advancement of the oral oxyntomodulin (OXM) program with OPKO, including positive PK/PD results and a planned Phase 1 study, positions the company in the high-demand obesity and metabolic disorders market.
• The collaboration with OPKO provided $8.0 million in funding through an equity issuance, bolstering the company's financial resources for specific development programs.
• Preclinical data for oral GLP-2 analog (OPK-8801003) demonstrated a significantly longer plasma half-life (18 times longer than teduglutide) and sustained systemic exposure, supporting once-daily oral dosing for rare malabsorption conditions.
• The company's N-Tab platform continues to demonstrate its versatility and potential across multiple peptide programs (PTH, GLP-1/Glucagon, GLP-2).

Negatives

• The company reported an increased net loss of $8.423 million for the nine months ended September 30, 2025, compared to $7.183 million in the prior year.
• Operating losses increased by 17% to $8.487 million for the nine months ended September 30, 2025.
• Revenue for the nine months ended September 30, 2025, decreased by 58% to $42 thousand, with no revenue recognized in the three months ended September 30, 2025.
• The company has an accumulated deficit of $122.350 million and has incurred negative cash flows from operating activities since inception, raising substantial doubt about its ability to continue as a going concern.
• Existing cash resources are insufficient to fund the proposed Phase 3 program for EB613 in osteoporosis, requiring additional capital raises.
• Geopolitical risks related to the Israel-Hamas conflict and broader regional instability, while currently immaterial to operations, pose a potential threat to business and could impact capital raising efforts.

Risks

• Clinical development is a lengthy and expensive process with uncertain outcomes, potentially leading to additional costs, delays, or inability to commercialize product candidates.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; failure to obtain approval for product candidates would materially harm the business.
• Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results in later-stage trials.
• The scope, progress, and costs of developing product candidates (EB613, EB612, oral peptides for hypoparathyroidism, obesity, metabolic disorders, and gastrointestinal rare diseases) may change based on various factors.
• Inability to raise additional funds or consummate strategic partnerships could delay, limit, or reduce product development and other operations.
• Even if a product candidate receives marketing approval, it may fail to achieve sufficient market acceptance by physicians, patients, and payors.
• Failure to obtain or maintain adequate coverage and reimbursement for approved product candidates could limit marketability and revenue generation.
• Inability to obtain and maintain robust patent protection for product candidates could allow competitors to develop similar products, adversely affecting commercialization.
• Reliance on third parties to conduct clinical trials and supply/produce product candidates introduces external dependencies and risks.
• Interpretation of FDA feedback and guidance may impact clinical development plans.
• Operating as a development stage company with limited operating history and a history of operating losses, and the ability to fund future operations, is a significant risk.
• Competitive position against other products on the market or in development for target disease categories.
• Ability to establish and maintain development and commercialization collaborations.
• Ability to manufacture and supply sufficient material for clinical trials and future commercial requirements.
• The ultimate resolution of the Israel-Hamas conflict and broader regional instability, including involvement from Hezbollah, Iran, and its proxies, could impact operations and workforce, despite a recent ceasefire.
• A downgrade of Israel's credit rating (e.g., Moody's to Baa1) could make it more difficult to raise capital and negatively influence the market price of ordinary shares.

Future Outlook

The company anticipates continued significant expenses and losses as it advances its clinical candidates. Existing cash resources are expected to fund operations through mid-Q3 2026, but additional capital is required to initiate the Phase 3 program for EB613 in osteoporosis. An Investigational New Drug (IND) application for the oral OXM program is expected to be filed with the FDA in the first half of 2026. Management is continually evaluating various financing alternatives and strategic collaborations to secure future funding.

Management Comments

• Management is of the opinion that available funds as of September 30, 2025, will be sufficient to support operations under current plans through the middle of the third quarter of 2026, excluding the capital required for the EB613 Phase 3 program.
• Management continually evaluates various financing alternatives and strategic collaborations, as the company will need to finance future research and clinical development with additional capital.

Industry Context

Entera Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on oral peptide delivery, a challenging but potentially transformative area. Its lead candidate, EB613, targets osteoporosis, a large market with existing injectable treatments. The company's oral oxyntomodulin (OXM) program with OPKO positions it in the rapidly growing obesity and metabolic disorders market, competing with established GLP-1 agonists like semaglutide (Wegovy/Rybelsus). The FDA's agreement on a single Phase 3 study for EB613 is a significant de-risking event, potentially accelerating its path to market compared to traditional multi-study requirements. The development of oral GLP-2 for short bowel syndrome also addresses an underserved area, offering a non-injectable alternative.

Comparison to Industry Standards

• Oral OXM showed plasma levels consistent with those reported in humans for the highest subcutaneous dose of Wegovy (semaglutide) weekly injection, a standard of care for obesity treatment, suggesting competitive efficacy for a once-daily oral regimen.
• Oral GLP-2 analog (OPK-8801003) demonstrated a plasma half-life approximately 18 times longer than teduglutide, the currently approved GLP-2 agonist for short bowel syndrome, indicating a potentially superior dosing profile.
• EB613's Phase 2 results showed significant increases in both trabecular and cortical bone parameters, comparable to improvements observed in women more than 10 years post-menopause, aligning with the efficacy expectations for anabolic osteoporosis treatments.

Management Changes

Corporate Governance

Related Party Transactions

• Issuance of 40,993 ordinary shares to five non-executive board members on January 15, 2025, in lieu of cash board fees for Q4 2024.
• Grant of 142,545 options to purchase ordinary shares to five non-executive board members on January 15, 2025.
• Grant of options to purchase 954,000 ordinary shares to employees, executive officers, and a service provider on April 28, 2025.
• Grant of options to purchase 830,000 ordinary shares to the Chief Executive Officer and other executive officers on April 28, 2025.
• Grant of 259,650 Restricted Share Units (RSUs) to executive officers on April 28, 2025, including 26,316 RSUs to an entity controlled by an executive officer for services rendered in lieu of an annual cash bonus.

Stakeholder Impact

• **Shareholders**: Experience dilution from ongoing ATM program and equity issuances. Face increased net losses and a 'going concern' warning, but also benefit from clinical progress and strategic collaborations that could drive future value. Geopolitical risks could negatively influence share price.
• **Employees**: Research and some management personnel are located in Israel, exposing them to geopolitical risks, though operations have been largely unaffected to date. Equity compensation plans are in place.
• **Customers/Patients**: Potential for new oral treatment options for osteoporosis (EB613), hypoparathyroidism (EB612), obesity/metabolic disorders (oral OXM), and rare malabsorption conditions (oral GLP-2), offering more convenient and potentially effective therapies.
• **Creditors**: The 'going concern' warning and need for additional financing may increase perceived credit risk.
• **Partners (OPKO)**: Deepened collaboration with OPKO through equity investment and shared development costs/proceeds, indicating a strong commitment to the oral OXM program.

Next Steps

• Initiate the single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study for EB613 in women with postmenopausal osteoporosis, pending additional funding.
• Continue the Phase 1 Safety and PK Study for the next generation of EB613, initiated in November 2025.
• Plan and initiate a Phase 1 study for oral OXM (GLP-1/Glucagon tablet) in collaboration with OPKO.
• File an Investigational New Drug (IND) application for oral OXM with the FDA in the first half of 2026.
• Secure additional capital to fund the EB613 Phase 3 program and ongoing operations beyond mid-Q3 2026.

Key Dates

Recommendation

Entera Bio presents a mixed bag for investors. On one hand, the company has made significant clinical and strategic progress, particularly with the FDA's agreement on a single Phase 3 study for EB613 and the promising collaboration with OPKO in the high-growth obesity market. These developments could be substantial value drivers if successful. On the other hand, the financial performance shows increasing losses, a substantial accumulated deficit, and an explicit 'going concern' warning, indicating a critical need for further capital. The geopolitical risks in Israel, while currently deemed immaterial to operations, add an unpredictable layer of uncertainty. Given the high-risk, high-reward nature of clinical-stage biotech, coupled with the immediate financial challenges and the need for significant future funding, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to secure the necessary funding for its Phase 3 program and the continued progress of its clinical pipeline, especially the oral OXM program, before making further investment decisions. The current valuation likely reflects both the potential upside and the significant execution risks.

Keywords

Entera Bio, ENTX, Oral Peptides, N-Tab platform, Osteoporosis, EB613, PTH(1-34), Hypoparathyroidism, EB612, Obesity, Metabolic Disorders, GLP-1/Glucagon, Oxyntomodulin, OPKO Health, GLP-2, Short Bowel Syndrome, Clinical Trials, Phase 3, FDA, Biotechnology, Pharmaceuticals, Going Concern, Capital Raise, Israel-Hamas Conflict